Caris Partners with UCSF to Advance Precision Oncology
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy CAI?
Source: Newsfilter
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Scientific Discovery Enhancement: UCSF's participation will bolster the alliance's scientific discovery capabilities, enhancing clinical outcomes for cancer patients through shared advanced molecular insights, highlighting the significance of precision medicine in cancer care.
- Data-Driven Innovation: Caris leverages its advanced AI-driven platform and extensive multimodal database to support alliance members in prioritizing therapeutic options and identifying clinical trial opportunities, thereby advancing personalized patient care.
- Commitment to Equity and Innovation: As an NCI-designated cancer center, UCSF is dedicated to accelerating breakthroughs in cancer detection, treatment, and survivorship by integrating laboratory discoveries with clinical trials, demonstrating a strong commitment to scientific excellence and patient care.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.830
Low
30.00
Averages
36.17
High
40.00
Current: 20.830
Low
30.00
Averages
36.17
High
40.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, aiming to enhance transparency and investor confidence through a live webcast discussing key financial metrics.
- Webcast Details: The earnings call is scheduled for 3:30 p.m. CT (4:30 p.m. ET), with a live link provided to ensure investors can access the latest company updates in real-time.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on innovative precision medicine solutions, committed to transforming healthcare through comprehensive molecular profiling.
- Technological Edge: The company leverages advanced AI and machine learning to create a large-scale clinico-genomic database, supporting the development of precision medicine diagnostic solutions that enhance early detection and therapy selection capabilities.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, and will host a live webcast at 3:30 p.m. CT to provide insights into its financial performance to investors.
- Webcast Details: The webcast will be accessible via the Caris Life Sciences website, allowing investors to view a replay shortly after the call, ensuring timely communication and transparency of information.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on precision medicine, actively developing and commercializing innovative solutions to transform healthcare.
- Technological Edge: By leveraging comprehensive molecular profiling and advanced AI technologies, Caris has created a large-scale clinico-genomic database aimed at analyzing the molecular complexity of diseases, thereby advancing precision medicine diagnostic solutions.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Collaborative Research Enhancement: UCSF's participation will deepen collaborative research with Caris POA members, leveraging Caris' AI-driven platform and multimodal database to improve clinical outcomes for cancer patients and advance personalized therapies.
- Data Resource Sharing: Caris POA members will gain access to one of the industry's largest multimodal databases, containing billions of data points, which will help prioritize therapeutic options and identify beneficial clinical trial opportunities, enhancing patient treatment outcomes.
- Precision Medicine Outlook: As an NCI-designated cancer center, UCSF's scientific discoveries and patient-centered cancer care will provide robust support for Caris' mission, driving breakthroughs in cancer detection, treatment, and survivorship.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Scientific Discovery Enhancement: UCSF's participation will bolster the alliance's scientific discovery capabilities, enhancing clinical outcomes for cancer patients through shared advanced molecular insights, highlighting the significance of precision medicine in cancer care.
- Data-Driven Innovation: Caris leverages its advanced AI-driven platform and extensive multimodal database to support alliance members in prioritizing therapeutic options and identifying clinical trial opportunities, thereby advancing personalized patient care.
- Commitment to Equity and Innovation: As an NCI-designated cancer center, UCSF is dedicated to accelerating breakthroughs in cancer detection, treatment, and survivorship by integrating laboratory discoveries with clinical trials, demonstrating a strong commitment to scientific excellence and patient care.
See More
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Access Gap in Trials: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: A meta-analysis in the Journal of the National Cancer Institute found that 55% of cancer patients offered a trial agree to participate, suggesting that access and infrastructure, rather than patient willingness, are the main barriers, which Caris addresses through rapid molecular profiling and trial matching.
- Integrated Technology Advantage: The Caris RIT solution integrates comprehensive molecular profiling, automated trial matching, and streamlined site activation, ensuring that patients can transition from molecular analysis to trial enrollment in approximately two weeks, significantly enhancing treatment accessibility.
- Data-Driven Decision Making: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, supporting clinical decision-making and driving the standardization of precision medicine, ensuring every cancer patient receives a treatment plan informed by their molecular profile.
See More
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Clinical Trial Access Gap: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: Among cancer patients offered trials, 55% agree to participate, suggesting that the main barriers are access and infrastructure rather than patient willingness; Caris's rapid molecular profiling and trial matching are expected to significantly enhance patient enrollment rates.
- Rapid Trial Matching: The RIT solution can move from molecular profiling to patient enrollment in approximately two weeks, and as quickly as five days, ensuring patients receive care locally while minimizing the burden of long-distance travel, thereby improving their treatment experience.
- Extensive Database Support: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, facilitating precise trial matching and advancing the adoption of precision medicine to ensure every cancer patient receives treatment informed by their molecular profile.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, aiming to enhance transparency and investor confidence through a live webcast discussing key financial metrics.
- Webcast Details: The earnings call is scheduled for 3:30 p.m. CT (4:30 p.m. ET), with a live link provided to ensure investors can access the latest company updates in real-time.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on innovative precision medicine solutions, committed to transforming healthcare through comprehensive molecular profiling.
- Technological Edge: The company leverages advanced AI and machine learning to create a large-scale clinico-genomic database, supporting the development of precision medicine diagnostic solutions that enhance early detection and therapy selection capabilities.
See More
Caris Life Sciences to Report Q1 2026 Financial Results on May 7
- Earnings Announcement: Caris Life Sciences will report its Q1 2026 financial results on May 7, 2026, and will host a live webcast at 3:30 p.m. CT to provide insights into its financial performance to investors.
- Webcast Details: The webcast will be accessible via the Caris Life Sciences website, allowing investors to view a replay shortly after the call, ensuring timely communication and transparency of information.
- Company Overview: Caris Life Sciences is a leading patient-centric next-generation AI TechBio company focused on precision medicine, actively developing and commercializing innovative solutions to transform healthcare.
- Technological Edge: By leveraging comprehensive molecular profiling and advanced AI technologies, Caris has created a large-scale clinico-genomic database aimed at analyzing the molecular complexity of diseases, thereby advancing precision medicine diagnostic solutions.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Collaborative Research Enhancement: UCSF's participation will deepen collaborative research with Caris POA members, leveraging Caris' AI-driven platform and multimodal database to improve clinical outcomes for cancer patients and advance personalized therapies.
- Data Resource Sharing: Caris POA members will gain access to one of the industry's largest multimodal databases, containing billions of data points, which will help prioritize therapeutic options and identify beneficial clinical trial opportunities, enhancing patient treatment outcomes.
- Precision Medicine Outlook: As an NCI-designated cancer center, UCSF's scientific discoveries and patient-centered cancer care will provide robust support for Caris' mission, driving breakthroughs in cancer detection, treatment, and survivorship.
See More
Caris Partners with UCSF to Advance Precision Oncology
- Network Expansion: The UCSF Helen Diller Family Comprehensive Cancer Center's inclusion in the Caris Precision Oncology Alliance strengthens the global network, expected to accelerate advancements in precision oncology and biomarker-driven research.
- Scientific Discovery Enhancement: UCSF's participation will bolster the alliance's scientific discovery capabilities, enhancing clinical outcomes for cancer patients through shared advanced molecular insights, highlighting the significance of precision medicine in cancer care.
- Data-Driven Innovation: Caris leverages its advanced AI-driven platform and extensive multimodal database to support alliance members in prioritizing therapeutic options and identifying clinical trial opportunities, thereby advancing personalized patient care.
- Commitment to Equity and Innovation: As an NCI-designated cancer center, UCSF is dedicated to accelerating breakthroughs in cancer detection, treatment, and survivorship by integrating laboratory discoveries with clinical trials, demonstrating a strong commitment to scientific excellence and patient care.
See More
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Access Gap in Trials: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: A meta-analysis in the Journal of the National Cancer Institute found that 55% of cancer patients offered a trial agree to participate, suggesting that access and infrastructure, rather than patient willingness, are the main barriers, which Caris addresses through rapid molecular profiling and trial matching.
- Integrated Technology Advantage: The Caris RIT solution integrates comprehensive molecular profiling, automated trial matching, and streamlined site activation, ensuring that patients can transition from molecular analysis to trial enrollment in approximately two weeks, significantly enhancing treatment accessibility.
- Data-Driven Decision Making: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, supporting clinical decision-making and driving the standardization of precision medicine, ensuring every cancer patient receives a treatment plan informed by their molecular profile.
See More
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Clinical Trial Access Gap: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: Among cancer patients offered trials, 55% agree to participate, suggesting that the main barriers are access and infrastructure rather than patient willingness; Caris's rapid molecular profiling and trial matching are expected to significantly enhance patient enrollment rates.
- Rapid Trial Matching: The RIT solution can move from molecular profiling to patient enrollment in approximately two weeks, and as quickly as five days, ensuring patients receive care locally while minimizing the burden of long-distance travel, thereby improving their treatment experience.
- Extensive Database Support: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, facilitating precise trial matching and advancing the adoption of precision medicine to ensure every cancer patient receives treatment informed by their molecular profile.
See More
